PharmAbcine Partners with Over 30 Pharmaceutical Companies for 5 Days at Bio USA

[Asia Economy Reporter Hyunseok Yoo] PharmAbcine announced on the 2nd that it will hold virtual meetings with more than 30 pharmaceutical companies over five days through the digital conference of BioUSA, organized by the American Bio Association.

Held annually, ‘BIO Digital 2021 (BioUSA)’ is the world's largest pharmaceutical and biotech conference, with over 17,000 industry professionals and experts from more than 70 countries participating. This event will be held online again this year, with presentation sessions on the 10th and 11th of this month, followed by partnering from the 14th to the 18th.

PharmAbcine plans to hold online meetings with potential global partners through the BIO One-on-One Partnering™ system to share and promote information about the company’s status and new drug development candidates. A PharmAbcine representative stated, “Partnering meetings have been proposed by more than 30 confirmed global pharmaceutical companies as well as several companies of various nationalities,” adding, “During these meetings, we will share preclinical results and future clinical plans for innovative drug candidates currently under development, such as Olinvacimab, PMC-403, and PMC-309.”

PharmAbcine’s Olinvacimab is an anticancer agent that inhibits the formation of neovascularization to prevent cancer growth. In April, the company signed a joint clinical research agreement with the global pharmaceutical company Merck for a Phase 2 clinical trial combining Olinvacimab with Keytruda in patients with mTNBC.

Additionally, PharmAbcine is accelerating research and development to enter clinical trials next year based on preclinical results presented at global conferences for PMC-403, which is expected to have therapeutic effects on macular degeneration and cancer through vascular normalization, and PMC-309, an immune checkpoint inhibitor targeting VISTA.

Although these pipelines are currently in the preclinical stage, they are expected to become first-in-class innovative new drugs not yet available on the market, serving as growth drivers for PharmAbcine.